Dual-drug combination shows promise against diabetic eye disease in animal model

February 15, 2017

GAINESVILLE, Fla. -- A two-drug cocktail provided better protection against diabetes-related vision loss than a single drug during testing in rat models, a team of University of Florida Health and Dutch researchers has found.

Researchers say the drug combination is a promising and unique potential treatment for patients with diabetic retinopathy, a major cause of vision loss in middle-age diabetes patients. Diabetic retinopathy damages blood vessels in the retina at the back of the eye, leading to distorted vision or blindness. There were 4.2 million cases of diabetic retinopathy among people ages 40 and over in the United States, according to a 2016 estimate by the American Academy of Ophthalmology.

Now, researchers from UF and the Erasmus Medical Center in the Netherlands have shown that the two drugs were more effective than a single drug at reducing the symptoms of diabetic retinopathy within the animals' retinas. The findings were published recently in the journal Investigative Ophthalmology & Visual Science.

During the 12-week study, the two-drug treatment reduced capillary loss by 68 percent compared with 43 percent with the single drug. Known as angiotensin receptor neprilysin inhibitor, or ARNI, the cocktail is a combination of irbesartin (an angiotensin receptor blocker) -- a medication already being used to treat high blood pressure -- and the anti-diarrhea compound thiorphan, a neprilysin inhibitor. In the laboratory, its effectiveness was compared with using irbesartin alone.

The two drugs did not completely reverse the effects of diabetic retinopathy, but they slowed it in the animal models, said Tuhina Prasad, Ph.D., a postdoctoral associate in the UF College of Medicine's department of ophthalmology research and a co-author of the paper. Most significantly, Prasad said the two drugs were much more effective at decreasing inflammation, which is one of the main symptoms of diabetic retinopathy.

"If you can decrease that inflammation, it protects the retinal cells and delays the progression of the disease," Prasad said.

The two-drug combination was also more effective than the lone drug at reducing cell death in the retina after 12 weeks in the rat models. The two drugs produced a 51 percent reduction in cell death, while the single drug showed only a 25 percent reduction, according to the findings. That is potentially significant in the development of drugs to treat diabetic retinopathy because the disease is strongly associated with prolonged diabetes in patients, the researchers noted.

Before a treatment can be brought to patients, researchers still have some work ahead: The possible chronic side effects of the neprilysin enzyme inhibitor on the eye have yet to be studied. Likewise, the long-term effects of giving that inhibitor are still unknown.

Still, Prasad said, the newly discovered compound may someday be a promising option for the millions of people living with diabetic retinopathy.
-end-
Funding for the research was provided by grants from the National Institutes of Health, the American Diabetes Association and the Bright Focus Foundation. Other support was provided by the National Eye Institute and Research to Prevent Blindness.

University of Florida

Related Cell Death Articles from Brightsurf:

Cell death in porpoises caused by environmental pollutants
Environmental pollutants threaten the health of marine mammals. This study established a novel cell-based assay using the fibroblasts of a finless porpoise stranded along the coast of the Seto Inland Sea, Japan, to better understand the cytotoxicity and the impacts of environmental pollutants on the porpoise population.

Gold nanoparticles to save neurons from cell death
An international research team coordinated by Istituto Italiano di Tecnologia in Lecce (Italy) has developed gold nanoparticles able to reduce the cell death of neurons exposed to overexcitement.

New light shone on inflammatory cell death regulator
Australian researchers have made significant advances in understanding the inflammatory cell death regulatory protein MLKL and its role in disease.

Silicones may lead to cell death
Silicone molecules from breast implants can initiate processes in human cells that lead to cell death.

New players in the programmed cell death mechanism
Skoltech researchers have identified a set of proteins that are important in the process of apoptosis, or programmed cell death.

Tumors hijack the cell death pathway to live
Cancer cells avoid an immune system attack after radiation by commandeering a cell signaling pathway that helps dying cells avoid triggering an immune response, a new study led by UTSW scientists suggests.

How trans fats assist cell death
Tohoku University researchers in Japan have uncovered a molecular link between some trans fats and a variety of disorders, including cardiovascular and neurodegenerative diseases.

Bacteria can 'outsmart' programmed cell death
To be able to multiply, bacteria that cause diarrhoea block mediators of programmed cell death, a new study in 'Nature Microbiology' shows.

Cell death or cancer growth: A question of cohesion
Activation of CD95, a receptor found on all cancer cells, triggers programmed cell death -- or does the opposite, namely stimulates cancer cell growth.

Cell death blocker prevents healthy cells from dying
Researchers have discovered a proof-of-concept drug that can prevent healthy cells from dying in the laboratory.

Read More: Cell Death News and Cell Death Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.